Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Harmony Biosciences Holdings (HRMY) EBT Margin (2020 - 2025)

Harmony Biosciences Holdings (HRMY) has disclosed EBT Margin for 6 consecutive years, with 16.72% as the latest value for Q4 2025.

  • Quarterly EBT Margin fell 1118.0% to 16.72% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 24.76% through Dec 2025, down 207.0% year-over-year, with the annual reading at 24.76% for FY2025, 207.0% down from the prior year.
  • EBT Margin hit 16.72% in Q4 2025 for Harmony Biosciences Holdings, down from 28.18% in the prior quarter.
  • In the past five years, EBT Margin ranged from a high of 34.37% in Q4 2022 to a low of 13.03% in Q3 2021.
  • Historically, EBT Margin has averaged 23.62% across 5 years, with a median of 27.36% in 2022.
  • Biggest five-year swings in EBT Margin: soared 20703bps in 2021 and later tumbled -2030bps in 2024.
  • Year by year, EBT Margin stood at 26.83% in 2021, then increased by 28bps to 34.37% in 2022, then crashed by -31bps to 23.57% in 2023, then increased by 18bps to 27.9% in 2024, then crashed by -40bps to 16.72% in 2025.
  • Business Quant data shows EBT Margin for HRMY at 16.72% in Q4 2025, 28.18% in Q3 2025, and 24.76% in Q2 2025.